Anti-angiogenic compounds based on modulation of VEGF splicing

基于 VEGF 剪接调节的抗血管生成化合物

• 批准号: BB/P012035/1
• 负责人: Sebastian Oltean
• 金额: $ 1.49万
• 依托单位: University of Bristol
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FP012035%2F1
• 关键词: Anti; angiogenic; compounds; based; modulation

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

GTR目前尚未用于所有资助研究的摘要。这通常是因为提交提案时不需要摘要，但可能是因为它包含了敏感信息，例如个人详细信息。

项目成果

The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor

• DOI: 10.1101/2020.11.02.364570
• 发表时间: 2020-01-01
• 期刊: bioRxiv
• 作者: Barratt, J.;Aghabi, Y.;Legge, D.
• 通讯作者: Legge, D.

Pharmacology of Modulators of Alternative Splicing.

• DOI: 10.1124/pr.115.011239
• 发表时间: 2017-01
• 期刊: Pharmacological reviews
• 影响因子: 21.1
• 作者: Bates DO;Morris JC;Oltean S;Donaldson LF
• 通讯作者: Donaldson LF

The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor.

• DOI: 10.1002/1878-0261.13101
• 发表时间: 2022-03
• 期刊: Molecular oncology
• 影响因子: 6.6
• 作者: Legge D;Li L;Moriarty W;Lee D;Szemes M;Zahed A;Panousopoulos L;Chung WY;Aghabi Y;Barratt J;Williams R;Pritchard-Jones K;Malik KTA;Oltean S;Brown KW
• 通讯作者: Brown KW

Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion.

• DOI: 10.1136/jclinpath-2015-203125
• 发表时间: 2016-02
• 期刊: Journal of clinical pathology
• 影响因子: 3.4
• 作者: Bullock N;Potts J;Simpkin AJ;Koupparis A;Harper SJ;Oxley J;Oltean S
• 通讯作者: Oltean S

The many faces of SRPK1.

• DOI: 10.1002/path.4846
• 发表时间: 2017-03
• 期刊: The Journal of pathology
• 作者: Bullock N;Oltean S
• 通讯作者: Oltean S